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Successful adoptive immunotherapy (AIT) for cancer relies on the infusion of in 
vitro expanded, tumor-reactive lymphocytes with a goal of generating productive tumor 
immunity. Previously, our lab has developed a protocol to activate selectively tumor-
reactive T lymphocytes in vitro using two pharmacologic agents, bryostatin-1 and 
ionomycin. Following the pharmacological stimulation, conventionally, IL-2 is added to 
stimulate in vitro proliferation. In this report, alternate cytokines from the common 
cytokine receptor γ-chain family, namely IL-7 and IL-15, were explored as the alternative 
 vi
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cytokine supplements. We found that tumor DLN cells activated in vitro with B/I and 
cultured in IL-7/15 alternate common γ-chain cytokines expanded better than IL-2 cultured 
cells. Furthermore, immunosuppressive myeloid-derived suppressor cells from the tumor 
microenvironment were targeted with a chemotherapeutic agent, gemcitabine. Despite 
combining gemcitabine and the T lymphocytes expanded in IL-7/15, AIT failed to induce 
regression of large established 4T1 mammary flank tumors.    
 
  
 
 
 
CHAPTER 1 Introduction 
 
 
1.1 Cancer: Challenges 
 Despite the advances in cancer research, according to a 2009 American Cancer 
Society report, cancer accounts for nearly one-quarter of deaths next to only heart diseases 
in the United States alone. Worldwide, one in eight deaths is due to cancer and it exceeds 
the number of deaths caused by AIDS, tuberculosis, and malaria combined. The 
corresponding estimates for total cancer deaths in 2007 were 7.6 million, or about 20,000 
cancer deaths a day, with 2.9 million in economically developed countries and 4.7million 
in economically developing countries. By 2050, the global burden is expected to grow to 
27 million new cancer cases and 17.5 million cancer deaths. Moreover, both the direct and 
indirect financial cost of cancer is also extensive (1). 
 Cancer cells are defined by the lack of regulation in cell proliferation and 
homeostasis. Several research findings indicate that tumorigenesis in humans is a multistep 
process and these genetic altering steps drive the transformation of normal human cells 
into highly malignant derivatives. Hanahan et al. categorizes the six main physical 
alterations common in cancer cells as: self-sufficiency in growth signals, insensitivity to 
growth-inhibitory signals, evasion of programmed cell death (apoptosis), limitless 
 1 
   
replicative potential, sustained angiogenesis, and tissue invasion and metastasis (2). Cancer 
cells escape the terminal differentiation and quiescence steps important in normal cell 
homeostasis. In order to obtain such properties, tumor cells produce their own growth 
factors or transform the normal growth factors from the hosts. Furthermore, the signaling 
pathways of mitogenic stimuli are constitutively activated by overexpression or by 
mutation of signal transduction signals in tumor cells. Tumor cells can also directly de-
regulate cell cycle regulation. Cancer cells obtain these new characteristics to avoid the 
antitumor defense mechanisms of the normal cells. Deregulations in these multiple 
regulatory circuits act as rate-limiting steps in tumor progression and add to the complexity 
of cancer cells (3). 
 There are several methods to treat cancer including surgery, radiation, 
chemotherapy, hormones, and immunotherapy. While standard treatments, like 
chemotherapy and radiation therapy, are used on cancer patients, the toxicity of adverse 
reactions can be a serious problem (4). On the other hand, immunotherapy is a relatively 
nontoxic cancer therapy that can be used alone or in conjunction with other therapies (5). 
The goal of immunotherapy is to use the host immune system to augment protective 
antitumor immunity and to disrupt the regulatory circuits that maintain tumor progression 
and tolerance (6). 
 
1.2 Overview of Innate and Adaptive Antitumor Immunity 
 2
   
 The idea that the immune system can recognize and respond to carcinomas, which 
are after all derived from the host, was first proposed by Paul Ehrlich in 1909. However, it 
was not until the 1950s, as immunologists gained a better understanding of transplantation 
and tumor immunobiology, that the Ehrlich theory could be validated. With the availability 
of inbred strains of mice, the animal models demonstrated that the syngeneic transplants of 
tumors were immunologically distinguishable from normal cells. Macfarlane Burnet and 
Lewis Thomas formally introduced the term “immunosurveillance” to describe the 
endogenous immune system components recognizing and eliminating the nascent 
transformed cells (7, 8). 
 In addition to identifying the cellular effectors of cancer immunosurveillance, two 
additional key studies revealed the effector functions of these cellular immune 
components.  First, Dighe et al. showed that endogenously produced interferon γ (IFN- γ) 
protected the host against the growth of transplanted tumor and the formation of primary 
chemically induced and spontaneous tumors (10). The second important observation was 
that C57Bl/6 mice lacking perforin were more vulnerable to MCA-induced tumor 
formation compared to the naïve wild-type mice. Perforin is a part of the cytolytic granules 
of cytotoxic T cells and natural killer (NK) cells that is involved in lymphocyte-dependent 
killing of many different target cells, including tumor cells (7, 8). 
 The host immune system can be categorized into two general responses: innate and 
adaptive immune response (see appendix A). The innate immune response refers to the 
first line of barriers to combat a wide range of pathogens but lacks pathogen specificity and 
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longevity. In addition to the physical and chemical barriers of the host, the innate immune 
system has cellular component including granulocytes and natural killer cells. In contrast, 
an adaptive immune response takes time to develop and is highly specific to the pathogen. 
The adaptive immunity involves the selection and amplification of clones of lymphocytes 
(B and T cells) bearing receptors that recognize the foreign antigen (a term derived from a 
substance that can stimulate antibody generation) (11, 12). The adaptive immune system 
can be further divided into humoral and cellular adaptive immunity. The former refers to 
the B cell receptors recognizing antigens from the extracellular environment and 
differentiating into effector plasma cells that secrete antibodies and into memory B cells. 
However, it is the function of the T lymphocytes, also known as the cell-mediated immune 
response, which control intracellular pathogens, to activate B cell responses to most 
pathogens, and play a key role in maintaining antitumor immunity.  
 T lymphocytes develop in the thymus and are composed of two main classes: one 
of which has a surface marker CD4 (CD4 T cells) and the other with CD8 (CD8 or 
cytotoxic T cells). The CD4 T cells are activated by the antigen epitopes bound to MHC II 
which are only located on the antigen-presenting cells (B cells, macrophages and dendritic 
cells). The CD4 effector subsets currently characterized are: T helper (TH) cells (which can 
be divided into TH1 and TH2 cells), TH17, and several regulatory T cell subsets. TH1 cells 
have a dual function of controlling intracellular pathogens and activating macrophages via 
various cytokines such as interleukin-2 (IL2), tumor necrosis factor-β (TNF-β), and 
interferon-γ (IFN- γ). TH2 cells are entirely dedicated to the activation of the naïve B cells 
to produce antibody. TH17 cells help to recruit neutrophils to sites of infection early in the 
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adaptive immune response. Regulatory T cells (Tregs) tend to inhibit immune activities 
and are important in preventing uncontrolled immune responses and autoimmunity (11, 
12). 
 There are several key findings that demonstrate the cellular basis of cancer 
immunosurveillance and involvement of both the adoptive and innate immune responses. 
One of the studies involved the gene-target mice lacking the recombinase activating gene 
(RAG-2). Mice lacking either RAG-2 or its obligate partner, RAG-1, cannot rearrange 
lymphocyte antigen receptors, which inhibits production of peripheral αβ T cells, B cells, 
natural killer cells, or γδ T cells. The importance of RAG-2 study is that RAG-2 expression 
is limited to cells of the lymphoid system, thus allowing researchers to exclusively study 
the effects of host lymphocyte deficiency. After subcutaneous injection of the chemical 
carcinogen 3’-methycholanthrene (MCA), RAG-2 knockout mice (RAG-2-/-) developed 
sarcomas at the injection site faster and with greater frequency when compared with the 
control group. RAG-2-/- mice were also more prone to spontaneous epithelial tumors. 
These findings reveal that lymphocytes are important protectors against both chemically-
induced and spontaneous tumor formation. Furthermore, Smyth et al. demonstrated that 
natural killer (components of innate immune system) and natural killer T cells also 
participate in cancer immunosurveillance. C57BL/6 mice, depleted of both natural killer 
and natural killer T cells using the anti-NK1.1 mAb, were two or three times more 
susceptible to MCA-induced tumorigenesis (7, 8, 9). 
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 Cytotoxic T cells carry CD8 surface marker and are stimulated by the antigenic 
peptide bound to major histocompatibility complex class I (MHC I) which are found on all 
nucleated cells (12). CD8 T cells have been identified as potent effectors of the adaptive 
antitumor immune response. The antigenic peptides recognized by these CD8 T cells are 
mostly non-mutated self-antigens that are also expressed by tumor cells. Although tumor-
specific CD4 T cells have also been identified, CD4 T cells can either help or hinder 
antitumor immune responses due to maintenance of Tregs (13). Since the first human 
tumor antigen was identified in 1991, many tumor antigens have been cloned. Different 
types of tumor antigens can be broadly classified into five categories: 1) cancer testis 
antigen, 2) tissue differentiation antigens, 3) overexpressed antigens, 4) unique tumor 
antigens and 5) viral antigens. In addition to tumor antigens presented on MHC molecules, 
transformed tumor cells also overexpress other molecules that can be recognized by the 
adaptive immune system as neoplastic (8). For example, among the most studied 
overexpressed oncogenic proteins is HER-2/neu. HER-2/neu is a growth factor receptor 
that is overexpressed in 30% of breast and ovarian cancers and other adenocarcionmas. 
Numerous studies have shown that antibody, helper T cell and cytotoxic CD8 T cell 
respond against HER-2/neu-positive cancer cells (14). Thus due to the immunogenicity of 
tumor cells, T lymphocytes can be used in immunotherapy to fight cancer. 
 
1.3 Adoptive Immunotherapy: Opportunities 
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 Immunotherapy can be categorized into two types: active and passive. The active 
immunotherapy stimulates the patient’s own immune system by direct administration of 
therapeutic cancer vaccines in vivo (12). Cancer vaccines include genetically modified 
tumor cells, antigen-loaded dendritic cells, and purified tumor antigens all aim to stimulate 
the adoptive immune system (17). However, in spite of large number of patients treated 
with vaccines, exceedingly low objective response rates are reported and cancer vaccines 
used alone cannot induce regression of invasive, vascularized tumors. Moreover, although 
immune T cells sensitive to tumor antigens can be generated by direct immunization 
(active immunotherapy), there are no cancer vaccine models that demonstrate that 
vacularized tumors can be rejected by this method. On the other hand, the passive 
immunotherapy has been more encouraging and shown consistent antitumor effects in 
rejecting large vascularized tumors in mice under appropriate conditions (16). Passive or 
adoptive immunotherapy (AIT) refers to the reintroduction of the cancer-reactive T cells, 
originally harvested from the cancer patients, which are then expanded and manipulated in 
vitro in order to generate productive antitumor responses (12, 6). 
 In adoptive immunotherapy, various mature T lymphocytes with antitumor activity 
are transferred into a tumor-bearing host with the goal of eliminating a tumor and 
preventing its recurrence (15). Three criteria are required for such immunologic destruction 
of established tumors: 1) sufficient numbers of immune cells must be generated in vivo 
that are highly sensitive to tumor antigens, 2) these immune components must traffic to 
and infiltrate the tumor stroma, and 3) once reaching the tumor site, these immune 
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effectors must manifest appropriate actions such as direct lysis or cytokine secretion than 
can cause tumor destruction (16).  
 When planning for successful AIT, the following factors must be taken into 
consideration: tumor type, route of AIT of immune effector cells, stage or size of tumor to 
be treated, location of tumor, immune effector cells to be transferred, source of effector 
cells, and the mechanism for ex vivo stimulation of effector cells including additional 
drugs or cytokines. When selecting a tumor model, since human tumors are weakly 
immunogenic, using too immunogenic tumor strain can result in deceptively easy tumor 
rejection. Also, generation of highly active T lymphocytes with specific reactivity against 
tumor antigen is critical for effective AIT (18). Although lymphokine-activated killer cells 
(LAK) and monocytes/macrophages can be used as AIT effectors cells, T cells have been 
identified as the most potent effectors of the adaptive antitumor immune response (12). 
Specifically, CD8 cytotoxic T lymphocytes are the primary effector cells used in adoptive 
T cell therapy.  
 There are various potential sources of T cells from the tumor-bearing host, 
including peripheral blood, tumor biopsies, lymph nodes and spleen. Obtaining T cells 
from the peripheral blood may be easier but higher frequency of tumor reactive T cells can 
be found in tumor biopsies (tumor-infiltrating lymphocytes) (6). However, harvesting 
sufficient amount of tumor-infiltrating lymphocytes can be difficult, though, this approach 
has been used successfully in patients with melanoma (18). Furthermore, tumor-infiltrating 
lymphocytes may require co-administration of high-dose interleukin-2 in generating 
antitumor responses in vivo, which may be harmful to the patients. The spleen can also be 
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a source of lymphocytes though the immunizing tumor cells need to be strongly 
immunogenic in order to activate the spleen cells. Based on our lab’s previous findings, the 
lymph nodes draining the primary tumor site have been a good source of tumor reactive T 
lymphocytes. We have found that the popliteal lymph nodes contain T lymphocytes once 
they are activated by the tumor cells injected into a footpad. Adoptive transfer of these 
effector cells after further activation and expansion in vitro into the tumor-bearing host can 
be delivered by intravenous (IV) (12). 
 For adoptively transferred T cells to proliferate and maintain effector functions in 
vivo, the host environment must be also prepared to optimize the AIT. One of the ways to 
precondition a favorable host environment is by lymphodepletion. According to Gattitoni 
et al., lymphopenic environment enables tumor-reactive T cells to destroy large tumors 
more effectively (13). Their finding is based on the long observation in mouse models that 
showed depletion of immune cells before AIT markedly improved the antitumor efficacy 
of transferred CD8 T cells. Although removing the host immune system for the efficacy of 
AIT seems counter-intuitive, there are several mechanisms that may explain the augmented 
efficacy. These factors include the elimination of host immunosuppressive cells such as 
CD4+ CD25+ regulatory T cells (Tregs), the depletion of endogenous cells competing for 
activating cytokines, and availability of antigen-presenting cells (APCs) (13). 
 Host immunosuppression in tumor-bearing hosts can be caused by several factors. 
Tregs are important for the maintenance of peripheral self-tolerance but suppress antitumor 
responses. Tregs represent about 5 to 10% of the CD4 T cell population and constitutively 
express CD25 (also known as IL2-Rα). They are also characterized by expression of the 
 9
   
transcription factor forkhead box P3 (Foxp3). Although Tregs control the key aspect of 
tolerance to self-antigens, tumor-associated antigens also derived from the self-antigen are 
masked by the Tregs and avoid the host immune system leading to detrimental 
immunosuppression (19). Other immune cells, including natural killer (NK) cells, natural 
killer T (NKT) cells, and most importantly myeloid-derived suppressor cells (MDSCs) 
have been demonstrated to suppress T cell functions. Although less is revealed about the 
immunosuppressive effects of NK and NKT cells, more is known about MDSCs. This 
heterogeneous cell population is composed of myeloid-derived lineage cells at various 
stages of differentiation, including monocytes, granulocytes, and dendritic cells. Increased 
frequencies of MDSCs have been reported with tumor progression and T cell dysfunction 
(13). 
 Furthermore, adoptively transferred antigen-specific T cells represent a small 
portion of the total T cell population residing in the host. Competition exists between 
transferred and irrelevant host T cells for a limited amount of resources such as cytokines 
and antigens required to support transferred CD8 T cell homeostasis for AIT. Such 
competition is known as the “cytokine sink” effect. Lymphodepletion can overcome 
cytokine sink effects and also decreases the competition at the surface of antigen-bearing 
antigen-presenting cells (APCs). Although lymphodepletion can reduce the number of 
APCs in vivo, it has been also linked to increasing the number of mature activated APCs 
which can facilitate the activation of transferred tumor-reactive T cells in vivo (13). 
 Host preconditioning by lymphodepletion can be achieved by several mechanisms 
including total body irradiation, genetic alteration, and systematic chemotherapy. Our lab 
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has administered the cytotoxic chemotherapy agent, cyclophosphamide (CYP), to 
precondition the host environment for AIT. Cyclophosphamide is a synthetic antineoplastic 
drug and an alkylating agent that interferes with the growth of rapidly proliferating cells. 
One possible mechanism of action is by cross-linking of tumor cell DNA (20). 
Cyclophosphamide has also been shown to remove tumor-induced suppressor T cells. 
Lutisak et al. demonstrated the mechanisms by which CYP can both decrease the number 
of Tregs and inhibit the suppressive capability of Tregs. Their results showed that low-
dose CYP administration decreases expressions of GITR and Foxp3 which are important in 
Treg function while enhancing apoptotic events and suppressing homeostatic proliferation 
of Tregs (19). 
 
1.4 Cytokines: Supplement to AIT 
 Successful adoptive immunotherapy requires not only a transfer of tumor-reactive 
T cells into the tumor bearing host, but also in vitro expansion of cancer-reactive T cells 
(6). Administration of cytokines has been known to amplify the AIT effect (12). 
Especially, the cytokines that use the receptors of the common cytokine-receptor γ-chain 
family (γc cytokines) are important for regulating T cell responses and stimulating T cell 
growth (21). Among the γc cytokines, interleukin-2 (IL-2), IL-7, and IL-15 are the critical 
cytokines for regulating lymphoid homeostasis. These cytokines can stimulate T cell 
activation, survival and proliferation in vitro. The common γc component in the receptors 
for these cytokines stimulates intracellular MAP kinase and PI3 kinase pathways that result 
in mitogenic and antiapoptotic signals (22).  
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 Activated CD4 and CD8 T cells produce IL-2 in response to T cell receptor ligation 
which binds to the heterotrimeric receptors that include IL-2Rα, IL-2/15Rβ, and γc (12, 
22). IL-2Rα recognizes IL-2 specifically with low affinity and has a short cytoplasmic 
domain. IL-2/15Rβ, as the name indicates, is a receptor chain that is shared both by the IL-
2 and IL-15 receptor. Once activated, it stimulates JAK3-, STAT5-, and AKT-dependent 
signaling pathways which are involved in cellular survival and proliferation. Studies with 
gene-targeted knockout phenotypes revealed IL-2 is critical in supporting T cell activation, 
and to a lesser degree, macrophages, natural killer cells, and B cells (12). 
 IL-15 is a both T cell and natural killer cell stimulatory factor (23). IL-15 and IL-
15Rα are expressed in thymus and support the intrathymic differentiation of T cells. The 
IL-15 receptor resembles the IL-2 receptor in that it is also a heterotrimeric receptor with 
IL-15Rα chain instead of the IL-2Rα chain and it binds to IL-15 with a high affinity (22). 
Although both IL-2 and IL-15 are similar in structure and function, they do have some 
contrasting functions. IL-2 can promote activation-induced T cell death while IL-15 
inhibits cellular death (23). Moreover, IL-15 enhances the proliferative capacity of 
memory T cell subsets (24). Memory T lymphocytes are a dynamic repository of antigen-
sensitized T lymphocytes that accumulate overtime. They provide immediate protection in 
peripheral tissues and increase recall responses to antigens in secondary lymphoid organs 
(25). Schluns et al. demonstrated that IL-15 and IL-15Rα are required to generate memory 
phenotype CD8 T cells in unimmunized mice and tumor-antigen specific memory CD8 T 
cells (21). 
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 While IL-15 signals are important in supporting memory CD8 T cell proliferation, 
the survival of the memory T cell population is supported by another common γc chain 
cytokine, IL-7. IL-7 contributes to the survival and proliferation of thymocytes during 
early stages of T cell development (23). The IL-7 receptor is a heterodimer with an IL-7α 
component which binds specifically to IL-7. Animals with deficient IL-7 or IL-7Rα 
demonstrated severe defects in T cell differentiation and deficiencies of both B and T 
lymphocytes indicating the importance of IL-7 in T cell development. IL-7 may also 
promote thymocyte survival by upregulating antiapoptotic thymocyte Bcl-2 expression 
(22). Furthermore, in vitro administration of IL-7 has been shown to enhance proliferation 
and survival of mature T cells, while exogenous IL-7 in vivo administration increased the 
numbers of CD4 and CD8 T cells (23).  
 
  
 
CHAPTER 2 Phenotyping different stages of T cell differentiation 
stimulated by both pharmacological agents and alternate 
gamma-chain cytokine family 
 
 
2.1 Introduction 
 Successful adoptive immunotherapy for cancer relies on the infusion of in vitro 
expanded, tumor-reactive lymphocytes with the goal of generating protective tumor 
immunity (6). Among the lymphocytes, CD8 cytotoxic T cells have been demonstrated as 
potent mediators of antitumor immunity (13). In order to activate and grow tumor-specific 
cytotoxic T lymphocytes, these lymphocytes must be periodically stimulated with 
autologous tumor antigen. Tumor cells can be used as stimulators but they may secrete 
immunosuppressive factors and are not clinically practical, since large amount of tumor 
cells are required. Thus, our lab has developed a protocol to activate selectively the tumor-
reactive T lymphocytes in vitro using two pharmacologic agents, bryostatin-1 and 
ionomycin. When T cells from the tumor-sensitized murine draining lymph nodes were 
activated with bryostatin-1 and ionomycin along with low-dose IL-2, not only did the 
lymphocytes expand better in vitro but also demonstrated antitumor efficacy in vivo (26, 
27). 
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 Exposure to both bryostatin-1 and ionomycin mimics an important T cell activation 
pathway (28). Following the ligation of tumor antigen with the T cell receptor, various 
proximal signaling complexes lead to activation of phospholipase C (PLC) which includes 
Ca2+ and DAG-induced responses. Phospholipase C is phosphorylated and activated by 
SLP-76, Vav 1, and LAT after T cell receptor ligation. Activated PLC then hydrolyzes the 
membrane lipid PI (4,5)P2 producing the second messengers inositol triphosphate (IP3) and 
diacylglycerol (DAG). The second messenger IP3 stimulates Ca2+ permeable ion channel 
receptors (IP3R) on the endoplasmic reticulum (ER) membrane, leading to the release of 
ER Ca2+ stores into the cytoplasm. T cell receptor induced production of DAG results in 
the activation of two pathways involving Ras and protein kinase C (PKC). PKC then 
phosphorylates numerous protein substrates downstream which activate genes involved in 
the function, survival, activation and homeostasis of T cells (29). 
 Brostatin-1 belongs to a class of macrocyclic lactones and is derived from marine 
bryozoans, Bugula neritina. It binds to the regulatory domains of protein kinase C (PKC) 
and regulates the pathway by both activation and inhibition. Short-term treatment of 
bryostatin-1 activates PKC while a long-term exposure results in PKC inhibition (30). It 
also has many immunomodulating properties including stimulation of IL-2 production and 
interferon-gamma in human peripheral blood lymphocytes, induction of IL-2 receptor on 
human T lymphocytes and inhibition of natural killer and lymphokine-activated killer 
(LAK) cells (31). However, it does not have tumor promoting properties that some other 
PKC activators (phorbol esters) demonstrate. Ionomycin is a calcium ionophore which 
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increases the intracellular Ca2+ concentration which are universal second messengers in 
eukaryotic cells (29, 33). 
 In addition to the pharmacologic agents, cytokines are also known to regulate T 
lymphocyte differentiation, survival and proliferation (23). Cytokines also play an 
important role in the differentiation of memory T cells. Memory is the hallmark of the 
adaptive immune system and is the ultimate goal of a protective immune response. There 
are four main events linked to the generation of memory T cells. These events include: 
initiation, clonal expansion, contraction and memory generation (21). Once the naïve T 
cells complete their maturation in the thymus, mature T cells circulate through the 
bloodstream and peripheral (secondary) lymphoid organs. Before activation, these naïve T 
cells maintain a low metabolic rate and divide only occasionally (homeostatic 
proliferation). T cells are activated when their receptors recognize a foreign antigen bound 
to MHC molecules and by interacting with the costimulatory receptor, which initiates a 
cascade of transcriptional and translational signals that allows for clonal expansion and 
acquisition of effector functions. After a vigorous clonal expansion phase, the great 
majority of effectors cells are eliminated by apoptosis during the contraction phase. A 
subpopulation of T cells remaining persists as memory T cells (33). 
 While IL-2 is critical in promoting effector T cell survival, T cell activation, and to 
a lesser degree, macrophages, natural killer cells, and B cells, IL-2 also enhances 
activation-induced cell death (AICD) of lymphocytes as a mechanism of self-tolerance (12, 
34). Although death of lymphocytes is an important homeostatic mechanism in the 
immune system and maintenance of peripheral tolerance to self antigens, AICD of 
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lymphocytes is disadvantageous in adoptive immunotherapy. Moreover, IL-2 is essential 
for regulatory T cells (Tregs) differentiation which may also hinder the effectiveness of 
adoptive immunotherapy. Naturally occurring Tregs (CD4+ CD25+ T cell population with 
constitutively expressed transcription factor forkhead box P3 or Foxp3) are important in 
controlling immunological tolerance to self-antigens but tumor-associated antigens can 
also be expressed as self which can enhance tumor protection (35).  
 Thus, other cytokines from the common cytokine receptor γ-chain family, namely 
IL-7 and IL-15, were explored as the alternative cytokine supplements. Both IL-7 and IL-
15 are essential regulators of T cell survival (33). Also, clear roles for IL-7 and IL-15 have 
been described in the maintenance of memory CD8 T cells. The memory CD8 T cell pool 
consists of effector memory cells that reside in peripheral tissues and central memory T 
cells located in lymphoid organs. Effector memory CD8 cells resemble phenotypic and 
functional similarities to effector cytotoxic CD8 T cells but persist even after antigen 
clearance. Central memory CD8 T cells are distinct from naïve, effector, and effector 
memory CD8 T cells. Characteristic phenotype properties of central memory cells include 
the expressions of CD44high, CD62Lhigh, IL-2Rβ+, Ly-6Chigh, and CCR7+. These markers 
are downregulated on effector memory T cells (36). 
 Physiologically, IL-7 is produced by a variety of stromal cells, keratinocytes, 
dendritic cells, neurons, and endothelial cells. IL-7 is critical for lymphopoiesis, T cell 
homeostasis, maintenance, and it also promotes T cell cytolytic responses. IL-7 is also an 
attractive cytokine agent for restoration of T cell activities in tumor-bearing hosts due to 
high level of the IL-7 receptor (CD127) expression on naïve T cells (37). While IL-7 
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receptors are found on naïve T cells, they are first downregulated after activation but then 
re-expressed on a subset of activated CD8 T cells that progress to become memory T cells 
(33). Memory T cells have an increased ability to survive in vivo when compared with 
naïve T cells. As IL-7 is a survival factor and memory CD8 T cells express high levels of 
IL-7Rα, so IL-7 may transmit the same survival signals to memory CD8 T cells as it does 
to naïve CD8 T cells (22). 
 Although IL-15 was originally identified as a cytokine with IL-2-like activity due 
to its common β- and γ-chain receptors, there are numerous data that support the idea that, 
unlike IL-2, IL-15 signals are important in maintenance of memory CD8 T cells (38). In 
fact IL-15 is a more potent proliferative agent for memory CD8 T cells than IL-2. 
Furthermore, IL-15 and IL-15Rα are required to maintain normal numbers of antigen-
specific memory CD8 T cells. Tan et al., using a cytokine knockout animal model, showed 
that in the absence of both IL-7 and IL-15, homeostatic proliferation of memory CD8 T 
cells completely failed.  
 Our lab has previously shown that bryostatin-1 and ionomycin (B/I) selectively 
activate tumor-reactive T cells with low expression of the lymph node homing receptor, L-
selectin (CD62Llow ), considered a marker for active effector cells. These CD62Llow 
lymphocytes demonstrated higher anti-tumor activity both in vitro and in vivo. However, 
these lymphocytes were cultured only in IL-2 (28). In a more recent report, we combined 
the effects of IL-7 and IL-15 on tumor DLN lymphocytes also activated in B/I. Compared 
to the cells grown in IL-2 alone, these IL-7/15 cells demonstrated greater proliferation and 
survival in the B16 melanoma model. Also IL-7/15 cells yielded higher in vitro interferon-
 18
   
gamma release and higher number of CD8 T cells with a central memory phenotype. 
However, in vivo adoptively transferred IL-7/15 cells were only slightly more effective 
against B16 lung metastases when compared to IL-2 cultured cells (39). However, in our 
unpublished report, we have used the 4T1 mammary carcinoma model to show 
significantly greater anti-tumor responses of IL-7/15 grown cells when used for AIT even 
at lower doses (20 and 40 million cells) (see appendix B). 4T1 is a poorly immunogenic, 
highly aggressive, metastasizing cancer. Unlike treating i.v. infusion-induced pulmonary 
metastases of B16 melanoma model, the 4T1 model aims to treat subcutaneous solid 
tumors and spontaneous metastases. Based on these findings, using the less immunogenic 
4T1 mammary carcinoma model, we aimed to investigate the proliferation and phenotypes 
of the tumor DLN lymphocytes activated in B/I and expanded in IL-7/15 compared to 
culture in IL-2. 
 
2.2 Materials and Methods 
Mice 
 Virus-free BALB/c mice (National Cancer Institute) were used between 8 and 12 
weeks of age. Animals were caged in groups of 6 or fewer and provided food and water ad 
libitum. All guidelines at Virginia Commonwealth University, which conform to the 
American Association for Accreditation of Laboratory Animal Care and the U.S. 
Department of Agriculture recommendations for the care and humane experimental use of 
animals, were followed. 
Tumor Cell Line 
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 4T1 mammary tumor cells were kindly provided by Dr. Jane Tsai at the Michigan 
Cancer Foundation, Detroit, Michigan. Cells were maintained in complete Dulbecco's 
Modified Essential Medium (DMEM) with 10% heat-inactivated fetal calf serum 
(Hyclone, Logan,UT), 1 mM sodium pyruvate (Mediatech, Inc, Herndon, VA), 100 U/ml 
penicillin (Invitrogen, Grand Island, NY), 100 mg/ml streptomycin, 0.075% sodium 
bicarbonate, and 10mM HEPES buffer. All cells were incubated in 250 ml T-flasks (PGC, 
Gaithersburg, MD) at 37 °C in humidified air with 5% CO2. Tumor cells were harvested 
for inoculation of mice with 0.05% trypsin–EDTA (Invitrogen), washed twice with 1× 
PBS and resuspended in 1× PBS. 
Draining Lymph Node (DLN) Sensitization and Harvesting DLN Cells 
 BALB/c mice were inoculated in one hind footpad with 1 x 106 viable 4T1 
mammary tumor cells. Ten days after sensitization, mice were euthanized by CO2 
inhalation and ipsilateral popliteal lymph nodes were harvested into complete RPMI under 
sterile conditions. Then the lymph node cells were crushed through a metal screen and 
single cell suspensions were prepared in complete RPMI. 
In Vitro Pharmacologic (Bryostatin and Ionomycin) Activation of Lymphocytes 
 The single cell suspensions of DLN were washed with RPMI and resuspended in 
RPMI at 1 x 106 cells/ml. DLN cells were incubated for 18 h with 5nM bryostatin 1 
(kindly provided by the National Cancer Institute, Bethesda, MD), 1mM ionomycin 
(Calbiochem, San Diego, CA), and 80U/ml of rIL-2 (Chiron, Emeryville, CA) at 37 °C  in 
humidified air with 5% CO2.  
Expansion of Lymphocytes in Culture 
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 Bryostatin-1/ionomycin-activated DLN cells were washed three times with 
complete warm RPMI and resuspended at 1 x 106 cells/ml. DLN cells were then expanded 
in complete RPMI supplemented with an additional 5% heat-inactivated fetal calf serum 
with either 40U/ml of rIL-2 or 10ng/ml each of IL-7 and IL-15 (Peprotech Inc, Rocky Hill, 
NJ). The cells were allowed to proliferate in culture for an additional 7-9 days and were 
split every 2-3 days with fresh cytokines in order to maintain 1x106 cells/ml concentration. 
CD8 T Cell Phenotype Assay and Treg Staining by Flow Cytometry 
 DLN cells were washed with flow buffer (2% fetal bovine serum and phosphate 
buffered saline of pH7.4) and brought up to 1 x 106 cells/ml in 100μl. Cells were first 
treated with anti-mouse CD16/CD32 (Mouse BD Fc Block) (BD Pharmingen, San Diego, 
CA). Cells were stained for 30 minutes for surface markers: anti-mouse PE-conjugated 
anti-CD62L-mAb (Biolegend, San Diego, CA); anti-mouse FITC-conjugated anti-CD44-
mAb and anti-CD25-mAb (Biolegend, San Diego, CA); and anti-mouse PE/CY5-
conjugated anti-CD8-mAb and anti-CD4-mAb (Biolegend, San Diego, CA). Unstained 
cells were used as the negative control. PE-conjugated rat IgG2a,λ was used as the isotype 
control for CD62L and Foxp3 (Biolegend, San Diego, CA). FITC-conjugated rat IgM was 
used as the isotype control for CD44 and CD25. Secondary intracellular staining for Foxp3 
was carried out after fixation and permeabilization using a PE-conjugated anti-mouse 
FoxP3 (FJK-16s) staining set (eBioscience, SanDiego, USA). PE/CY5-conjugated rat 
IgG2b,κ was used the isotype control for CD8 and CD4 (Biolegend, San Diego, CA). The 
freshly stained cells were analyzed on an ELITE Beckman Coulter flow cytometer. 50,000 
viable cells per sample were analyzed. 
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Cytokine Release Assay 
 DLN cells that have been activated with B/I cultured in either IL-2 or IL-7/15 were 
assayed for IFN-γ secretion in response to specific antigen. The lymphocytes were cultured 
in 24-well plates at 2x106 cells/ml with either no stimulants (negative control) or with a 
stimulator (irradiated 4T1 mammary tumor cells). Lymphocyte to stimulator ratio was 
10:1. After 24 hours of culture, supernatant was harvested and stored at -20°C until 
assayed using a mouse IFN-γ ELISA kit (BD Biosciences Pharmingen, San Diego, CA). 
Results reported are the mean values of duplicate ELISA wells ± SD. 
 
2.3 Results 
DLN cells grown in IL-7/15 expand better in vitro than in IL-2  
 Wildtype BALB/c mice were inoculated in one hind footpad with viable 4T1 
mammary tumor cells to sensitize the lymph nodes. Ten days after inoculation, mice were 
euthanized by CO2 inhalation and ipsilateral popliteal lymph nodes were harvested. Then 
the lymph node cells were activated with B/I regimen and were grown in vitro either in IL-
2 or IL-7/15 cytokines for 10 days. As indicated in Figure 1, IL-7/15 cells expand to 12 
fold increase by day 3 and IL-2 cells have expanded to 11.5 fold. By day 6, the fold 
increase difference between IL-7/15 and IL-2 was striking (40 fold for IL-7/15 and 11.4 
fold for IL-2). IL-7/15 cells continued to have higher number of viable cells extending to 
day 10 (68 fold for IL-7/15 and 18.9 fold for IL-2). 
Phenotypic polarization of cells cultured in IL-7/15 vs. IL2 
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 We have previously found that B/I regimen preferentially activate CD62Llow cells, 
which lead to a T cell population that is functionally enriched for tumor antigen-specific 
clones with antitumor activity. Such adoptively transferred cells seemed to reside 
predominantly in the CD8 T cell subset. However, these cells had previously only been 
expanded in IL-2 in vitro. Thus, we investigated whether the phenotypes of IL-2 expansion 
were different from the IL-7/15 expanded cells. On days 2, 6, and 9 of cell expansion, 
samples were taken from both IL-2 and IL-7/15 groups and were stained for CD8, CD44 
and CD62L. CD8 is a marker used for cytotoxic T cells. CD44 is a cell surface 
glycoprotein that is expressed by many cells but among CD8 T cells, its expression is 
upregulated after activation and remains high on memory T cells. CD62L, also known as 
L-selectin, acts as a homing receptor for T cells to lymph nodes. CD62L marker can also 
be used to distinguish subpopulations of the CD8 T memory cell as central memory CD8 T 
cells (CD62Lhigh) and effector memory CD8 T cells (CD62Llow). Figure 2 shows 
percentages of DLN cell by triple staining for (CD8, CD44, and CD62L) and histogram 
(for CD8) on days 2, 6, and 9. On day 2, when both IL-2 and IL-7/15 cells were expanding 
on the upward trend of the expansion curve, there is not much difference in the proportion 
of CD8+ cells (42.63% for IL-2 and 42.84% for IL-7/15). Percentages representing central 
memory (triple positive) for IL-2 and IL-7/15 were also similar (71.51% for IL-2 and 
77.11% for IL-7/15). By day 9, when the expansion difference between IL-2 and IL-7/15 
cultured cells is the greatest, IL-2 cells have significantly reduced central memory 
phenotype (CD44high/CD62Lhigh) but the IL-7/15 group maintained the memory phenotype 
(24.44% for IL-2 vs. 52.61% for IL-7/15). Also, IL-7/15 cultured cells maintained a high 
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proportion of CD8+ T cells while IL-2 cultured CD8+ cells began to decline (43.9% for 
IL-2 and 59.8% for IL-7/15).  
Treg staining higher in IL2 group than IL7/15 
 DLN cells expanded in either IL-2 or IL-7/15 were also analyzed for the presence 
of T regulatory cells (Tregs) on the same days. As shown in Figure 3, triple positive 
staining for CD4, CD25 and Foxp3 markers indicates Tregs. The histograms for each day 
also show viable CD4+ cells for each cytokine groups. On day 2, when the expansion 
difference is minimal, both the CD4+ cell population and percentages of Tregs are similar 
between IL-2 and IL-7/15 groups. However, as IL-7/15 cultured cells proliferate and 
expand more effectively, both the CD4 subset and Tregs decreased for IL-7/15 group 
compared to IL-2 group. Treg population declined from 15% to 2.6% of CD4+ cells on day 
9. Of note, since the CD4+ population is declining as well (from 41.7% to 35.9%), this 
triple stained Treg population is even more reduced in IL-7/15 cultured cells compared to 
cells from IL-2. However, IL-2 maintained both the CD4+ subset (42.1%, 43.1% and 
52.1% on days 2, 6, and 9 respectively) and the Treg population (14.2%, 7.3%, and 7.6% 
on days 2, 6, and 9 respectively). 
Tumor specificity by IL-7/15 Group vs.IL-2 Group 
 DLN cells that have been sensitized by B/I regimen and cultured in either IL-2 or 
IL-7/15 were assayed for IFN-γ secretion in response to specific antigen. The lymphocytes 
were cultured in 24-well plates at 2x106 cells/ml with either no stimulant (negative control) 
or with a stimulator (irradiated 4T1 mammary tumor cells). Lymphocyte to stimulator ratio 
was 10:1. Results are shown in Figure 4 and are reported as the mean values of duplicate 
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ELISA wells ± SD. Data shown are representative of three independent experiments. 
Contrary to our previous findings in B16 melanoma model, IL-2 cultured cells secreted 
more IFN-γ than IL-7/15 cultured cells when exposed to irradiated 4T1 mammary tumor 
cells. This high in vitro IFN- γ response of IL-2 group to 4T1 cells increased further by day 
10 of expansion. Previous studies have shown that this IFN-γ response is tumor antigen-
specific (60). 
 
2.4 Discussion 
 Adoptive cancer immunotherapy relies on the infusion of tumor reactive T cells 
into tumor-bearing hosts. This therapy utilizes ex vivo expansion of tumor reactive T cells 
where stimulatory pharmacological agents and cytokines can be applied to generate large 
numbers of such immune effector cells (40). In the experiments described in this chapter, 
we found that tumor DLN cells activated in vitro with B/I and cultured in IL-7/15 alternate 
common γ-chain cytokines expanded better than IL-2 cultured cells. This in vitro 
expansion finding is consistent with our previous report on the beneficial effects of 
combining IL-7 and IL-15 comparative to IL-2 alone in B16 melanoma model. B16 
melanoma-sensitized lymph node cells from C57B1/6 mice cultured in IL-7/15 
consistently resulted in much greater expansion of viable cells than in IL-2 in more than 
ten separate experiments. Not only did IL-7/15 induce greater rapid proliferative activity, 
but it also induced prolonged growth of T cells (39). 
 In addition to generating a large number of ex vivo antigen specific T lymphocytes 
to transfer, T cells must also preserve their effector functions and homing abilities of 
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trafficking to lymph nodes to induce tumor regression and elimination and protection from 
recurrence (41). The major function of CD8 effector T cells is to kill infected cells or 
malignant cells expressing viral or tumor antigen. Since cytotoxicity requires direct contact 
with the target cell, these cytotoxic cells must be able to migrate to different tissues, 
especially to sites of inflammation. This capacity of lymphocytes to enter tissues from 
blood depends upon the ability to adhere to endothelial cells while withstanding 
hydrodynamic shear stresses exerted by flowing blood. Tethering and rolling mechanisms 
are initiated by members of the selectin family (42). 
 Numerous research findings have indicated that antigen-activated CD8 T cells 
differentiate differently in trafficking phenotypes and functions when exposed to various 
common receptor γ-chain family cytokines. According to Klebanoff et al., in the presence 
of IL-15 cytokine, the CD8 T cells differentiated into central memory cells (a subset of 
memory phenotype) while IL-2 stimulated cells assumed a highly differentiated, effector 
and effector memory CD8 T cells (43). Our CD8 phenotype staining comparison for both 
IL-2 and IL-7/15 showed marked differences between the two groups on day 9 when their 
expansion differences are most pronounced. As expected, IL-7 and IL-15 maintained 
CD62Lhigh memory CD8 T cell population while IL-2 cultured cells lost much of CD62L 
expansion. 
 Central memory T cells (CD62Lhigh) are located in secondary lymphoid issue with 
limited migratory potential and have been proposed to show little cytolytic activity. On the 
other hand, effector memory cells (CD62Llow) reside in non-lymphoid tissues with 
promiscuous circulatory potential and exhibit cytolytic activity (21). Thus, T cells used for 
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current adoptive immunotherapy trials are commonly targeted for effector and effector 
memory CD8 T cell phenotypes and functions due to their strong lytic capacity and release 
of high IFN-γ (13). However, long-term immunological protection and ability to undergo 
self-renewal that can be manifested by memory CD8 T cell population has also attracted 
researchers to examine the therapeutic effects of memory T cell transfer therapy (43, 44, 
45). Klebanoff et al. evaluated the same IL-2 and IL-15 cultured CD8 T cell populations as 
mediators of immune response to an established B16 melanoma. They found that IL-15 
cultured antigen-specific cells with central memory T cell phenotype showed greater in 
vivo recall response compared to effector memory T cell population. This enhanced 
response was associated with the complete eradication of large, established B16 melanoma 
tumors (43, 44). We have also found significant anti-tumor responses of IL-7/15 grown 
cells when used for AIT in 4T1 mammary carcinoma model. Although  AIT with effector 
phenotype IL-2 group was successful in inducing tumor regression at a maximum AIT 
dose of 75 million cells, it was only memory-centered IL-7/15 group that consistently 
showed complete elimination of 4T1 tumor when lower doses (20 and 40 million cells) of 
AIT was utilized (unpublished Bear lab data).  
 Although previously we have observed a correlation between antitumor activity in 
vivo and IFN-γ release in vitro, this 4T1 model study showed that tumor regression may 
not be completely dependent on this cytokine (28). Klebanoff et al. showed that either IL-2 
or IL-15 group produced comparable, dose-dependent amounts of IFN-γ secretion (43, 44). 
Contrary to our previous findings in B16 melanoma model (39), IL-2 cultured cells in this 
report secreted more IFN-γ in vitro than IL-7/15 cultured cells when exposed to irradiated 
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4T1 mammary tumor cells. This finding corresponds to  findings of Gattinoni et al. in 
which they found that CD8 T cells that acquire effector properties and exhibit increased 
antitumor reactivity in vitro (e.g. IFN--γ release) are actually less effective at triggering 
tumor regression and cures in vivo. Furthermore, unlike IL-7/15, IL-2 enhances activation-
induced cell death (AICD) of lymphocytes as a mechanism of self-tolerance and is 
essential for regulatory T cells (Tregs) differentiation which may also hinder the 
effectiveness of adoptive immunotherapy (12, 34). We have found that IL-2 cultured cells 
maintained higher Treg populations compared to IL-7/15 group.  
 The result reported here, which demonstrates a different responsiveness of tumor 
DLN cells to IL-2 and IL-7/15 for in vitro expansion and memory phenotypes may 
contribute to achieving successful AIT. Our findings of IL-7/15 cultured cells effectively 
expanding and proliferating ex vivo after B/I treatment correlated with inducing tumor 
regression and complete elimination even with smaller doses of T cells needed for AIT 
transfer. This phenomenon may be further explored in terms of treating larger established 
tumors with fewer transferred cells; perhaps T memory cells grown in IL-7/15 can 
demonstrate faster and longer in vivo recall responses than cells grown in IL-2. 
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Figure 1: IL-7/15 induces greater growth of tumor DLN cells than IL-2 in vitro 
BALB/c mice were inoculated in one hind footpad with 1 x 106 viable 4T1 mammary 
tumor cells. Ten days after sensitization, mice were euthanized by CO2 inhalation and 
ipsilateral popliteal lymph nodes were harvested. DLN cells were incubated for 18 h with 
5nM bryostatin 1, 1mM ionomycin, and 80U/ml of rIL-2 at 37 °C in humidified air with 
5% CO2. DLN cells were then expanded in complete RPMI supplemented with an 
additional 5% heat-inactivated fetal calf serum with either 40U/ml of rIL-2 or 10ng/ml of 
IL-7 and IL-15. IL-7/15 cells expand to 12 fold increase by day 3 while IL-2 cells have 
only expanded to 11.5 fold. By day 6, the fold increase difference between IL-7/15 and IL-
2 is significant (40 fold for IL-7/15 and 11.4 fold for IL-2). IL-7/15 cells continue to have 
higher number of cells even to day 10 (68 fold for IL-7/15 and 18.9 fold for IL-2). 
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Figure 2: IL-7/15 expanded DLN cells maintain central memory CD8 T cell subsets 
and show higher CD8 T cells. 
4T1 mammary tumor cells sensitized DLN cells were incubated for 18 h with 5nM 
bryostatin 1, 1mM ionomycin, and 80U/ml of rIL-2. DLN cells were then expanded in 
either 40U/ml of rIL-2 or 10ng/ml of IL-7 and IL-15. On days 2 (2A), 6 (2B), and 9 (2C) 
of cell expansion, DLN cell samples were taken for CD8 memory phenotype surface 
staining. Percentages of triple positive staining gated on viable CD8 memory population is 
indicated by CD8+ CD62L+CD44+ staining in the upper right quadrant. The lower 
histogram indicates the percentages for CD8+ T cell population. Fluorescence of 50,000 
viable cells per sample was analyzed by flow cytometry. Data shown are representative of 
three independent experiments. 
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Figure 2A 
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Figure 2B 
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Figure 2C 
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Figure 3: IL-2 maintains higher number of immunosuppressive T regulatory cells 
(Tregs) when compared to IL-7/15 cell group.  
DLN cells expanded in either 40U/ml of rIL-2 or 10ng/ml of IL-7 and IL-15 were also 
analyzed for Treg (CD4+ CD25+ Foxp3+) population. On days 2 (3A), 6 (3B), and 9 (3C) 
of cell expansion, DLN cell samples were stained for Tregs following using a PE-
conjugated anti-mouse FoxP3 (FJK-16s) staining set. Percentages of triple positive staining 
gated on viable CD4 cell population are shown in the upper right quadrant. The lower 
histogram indicates the percentages of viable CD4+ T cell population. Fluorescence of 
50,000 viable cells per sample was analyzed by flow cytometry. Data shown are 
representative of three independent experiments. 
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Figure 3A 
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Figure 3B 
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Figure 3C 
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Figure 4: IL-2 expanded DLN cells show an increase in IFN-γ secretion in response to 
specific 4T1 antigen when compared to that of IL-7/15 group over the course of ex 
vivo culture. 
DLN cells that have been sensitized by bryostatin 1 and ionomycin cultured in either IL-2 
or IL-7/15 were assayed for IFN-γ secretion in response to specific and nonspecific 
antigen. The lymphocytes were cultured in 24-well plates at 2x106 cells/ml with either no 
stimulants (negative control) or with a stimulator (irradiated 4T1 mammary tumor cells). 
Lymphocyte to stimulator ratio was 10:1. After 24 hours of culture, supernatant was 
harvested and stored at -20°C until assayed using a mouse IFN-γ ELISA kit. Results 
reported as the mean values of duplicate ELISA wells ± SD. Data shown are representative 
of three independent experiments. 
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CHAPTER 3 Gemcitabine-Mediated Suppression of Myeloid-
Derived Suppressor Cells Combined with Adoptive 
Immunotherapy to Treat Established Tumor 
 
 
3.1 Introduction 
 Adoptive immunotherapy focuses on inducing and expanding cytotoxic T cells and 
improving the immune recognition of weak antigens expressed by tumors. However, 
tumor-induced immune suppression found in human patients and experimental animals 
with malignant tumors significantly impedes the effectiveness of immunotherapy and 
cancer immunosurveillance (46). There are several proposed mechanisms that may 
modulate tumor-induced immune suppression. Cancer-associated immune suppression can 
be facilitated by factors secreted by the tumor, the tumor microenvironment or by 
suppressive immune cells such as regulatory T cells. Among these factors, myeloid-
derived suppressor cells (MDSC) are identified as a major contributor to tumor-associated 
immunosuppression (47). 
 MDSCs are a heterogeneous population of undifferentiated cells that are derived 
from the myeloid, macrophage, and dendritic cell lineage. This population includes 
granulocyte, macrophage, dendritic cell, and early myeloid progenitors. Increased levels of 
MDSCs are reported with numerous pathologic conditions. In animal models, frequency of 
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MDSCs can be found in the spleens than in the tumor microenvironment. Human MDSCs 
have been reported in the bone marrow and peripheral blood of cancer patients with lung, 
breast, and head and neck cancer (46). MDSCs are also known as “immature myeloid 
cells,” “inhibitory macrophages,” and “early myeloid cells.” However, immunosuppressive 
MDSCs have a key phenotype that can be identified by two major cell surface markers, 
CD11b and Ly6G (previously known as Gr-1). CD11b is a specific marker for myeloid 
cells of the macrophage lineage and Gr-1 is a marker for granulocytes. MDSCs express 
low levels of MHC class II molecules and costimulatory molecules; thus, they do not 
induce effective antitumor responses due to the inability to process and present antigens 
(48). Furthermore, Yang et al. demonstrated that these CD11b+ Gr-1+ cells can acquire 
endothelial cell properties in the tumor microenvironment that can contribute to tumor 
angiogenesis in promoting tumor growth. MDSCs also downregulate expressions of the 
CD3ζ chains of T cell receptors, inhibiting antigen-specific responses from activated CD4 
and CD8 T lymphocytes (49). MDSCs have also been linked to triggering apoptotic death 
of CD8 T cells (50).  
 The immunosuppressive effects of MDSCs can be mediated by multiple 
mechanisms. MDSCs stimulate immunosuppressive cytokines, nitric oxide synthase type 2 
(iNOS or NOS2) and arginase-I (ARG1) metabolism of L-arginine into reactive oxygen 
species (ROS) and nitric oxide (NO). The expansion of MDSCs is associated with 
increased levels of growth factors including vescular endothelial growth factor (VEGFs) 
which inhibit dendritic cell differentiation. Also, MDSC reduction of CD3ζ chains of T 
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cell receptors has been accompanied by an increase in ARG1 activity. Activation of ARG1 
limits L-arginine availability in the tumor microenvironment and the formation of urea 
which can alter translation of mRNAs, further suppressing T cell functions. Additionally, 
high levels of iNOS and NO accompanied by MDSCs suppress IL-2 receptor signaling and 
increase reactive oxygen species and reactive nitrogen oxide species. These highly reactive 
oxidizing agents damage biological targets and contribute to immunosupression by T cell 
apoptosis, increased IL-2 instability, depressed T cell proliferation, and depression of 
CD3ζ chain expression (46). By direct contact with macrophages, MDSCs can also 
decrease macrophage IL-12 production while increasing IL-10 secretion (47).  
 Based on these immunosuppressive effects of MDSCs, elimination of MDSCs from 
the tumor bearing hosts has been proposed to enhance the adoptive immunotherapy. 
Kusmartsev et al. described a strategy of in vivo administration of all-trans-retinoic acid 
(ATRA) to tumor bearing animals. ATRA is a naturally occurring isomer of retinoic acid 
capable of inducing differentiation of a human leukemia cell line and acute promyelocytic 
leukemia cells. In vitro experiments with ATRA significantly reduced the presence of 
MDSCs in humans and mice. Combining the administration of ATRA and cancer vaccine 
demonstrated reduced immunosuprression and enhanced efficacy of the tumor vaccine in 
the animal model (52). Suzuki et al. examined the potential use of a chemotherapeutic 
agent, gemcitabine, in combination with immunotherapy to address the 
immunosuppressive effects of MDSCs. Gemcitabine HCl (GEM) is 2’-deoxy-2’, 2’-
difluorocytidine monohydrochloride (β-isomer) is a nucleoside analogue of cytidine that 
halts the DNA synthesis phase (S-phase) and blocks the progression of cells through the 
 43
   
G1/S-phase boundary (53). Their rationale for using GEM treatment were based on the 
observations of Nowak et al. that antiproliferative gemcitabine selectively preserves tumor-
specific CD4 and CD8 T cells while reducing the number of B cells. This study showed 
that administration of GEM at a physiological dose can significantly reduce the number of 
MDSCs in the spleens of tumor bearing animals while maintaining CD4 T cells, CD8 T 
cells, natural killer cells, and macrophages. Furthermore, the antitumor activity of CD8 T 
cells and activated natural killer cells were enhanced (54). 
 In the weakly immunogenic 4T1 mammary carcinoma model, we have recently 
reported that GEM can directly inhibit MDSCs and indirectly reduce the number of 
MDSCs by its cytotoxicity to the tumor cells. Based on these findings, AIT was performed 
to cure 4-day old 4T1 flank tumors. The donor AIT spleen cells were prepared from tumor-
bearing mice after in vivo GEM treatment which augmented the in vitro expansion of the 
splenic T cells and restored T cell function. However, the AIT treatment with these splenic 
T cells was ineffective against the established tumors (55). In this study, we investigate 
whether in vivo administration of GEM to the AIT recipient tumor-bearing mice has a 
therapeutic effect in eliminating established 4T1 mammary carcinoma. AIT T lymphocytes 
from the tumor-draining lymph nodes, rather than spleen cells, were prepared using the 
more effective IL-7/15 cytokine expansion protocol mentioned in the previous chapter.  
 
3.2 Materials and Methods 
Mice 
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 Virus-free BALB/c mice (National Cancer Institute) were used between 8 and 12 
weeks of age. Animals were caged in groups of 6 or fewer and provided food and water ad 
libitum. All guidelines at Virginia Commonwealth University, which conform to the 
American Association for Accreditation of Laboratory Animal Care and the U.S. 
Department of Agriculture recommendations for the care and humane experimental use of 
animals, were followed. 
Tumor Cell Line 
 4T1 mammary tumor cells were kindly provided by Dr. Jane Tsai at the Michigan 
Cancer Foundation, Detroit, Michigan. Cells were maintained in complete Dulbecco's 
Modified Essential Medium (DMEM) with 10% heat-inactivated fetal calf serum 
(Hyclone, Logan,UT), 1 mM sodium pyruvate (Mediatech, Inc, Herndon, VA), 100 U/ml 
penicillin (Invitrogen, Grand Island, NY), 100 mg/ml streptomycin, 0.075% sodium 
bicarbonate, and 10mM HEPES buffer. B16F10 melanoma tumor cells were kindly 
donated by Dr. Rodney Prell at Cell Genesys, Inc., South San Francisco, California.  
All cells were incubated in 250 ml T-flasks (PGC, Gaithersburg, MD) at 37 °C  in 
humidified air with 5% CO2. Tumor cells were harvested for inoculation of mice with 
0.05% trypsin–EDTA (Invitrogen), washed twice with 1× PBS and resuspended in 1× 
PBS. 
Draining Lymph Node (DLN) Sensitization and Harvesting DLN Cells 
 BALB/c mice were inoculated in one hind footpad with 1 x 106 viable 4T1 
mammary tumor cells. Ten days after inoculation, mice were euthanized by CO2 inhalation 
and ipsilateral popliteal lymph nodes were harvested into complete RPMI under sterile 
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conditions. Then the lymph node cells were crushed through a metal screen and single cell 
suspensions were prepared in complete RPMI. 
In Vitro Bryostatin and Ionomycin Activation 
 The single cell suspensions of DLN were washed with RPMI and resuspended in 
RPMI at 1 x 106 cells/ml. DLN cells were incubated for 18 h with 5nM bryostatin 1 
(kindly provided by the National Cancer Institute, Bethesda, MD), 1mM ionomycin 
(Calbiochem, San Diego, CA), and 80U/ml of rIL-2 (Chiron, Emeryville, CA) at 37 °C  in 
humidified air with 5% CO2.  
Expansion of Lymphocytes in Culture 
 Bryostatin-1/ionomycin-activated DLN cells were washed three times with 
complete warm RPMI and resuspended at 1 x 106 cells/ml. DLN cells were then expanded 
in complete RPMI supplemented with an additional 5% heat-inactivated fetal calf serum 
with 10ng/ml each of IL-7 and IL-15 (Peprotech Inc, Rocky Hill, NJ). The cells were 
allowed to proliferate in culture until peak growth and were split every 2-3 days in order to 
maintain 1x106 cells/ml concentration. 
Treatment of Established Tumors (Adoptive Immunotherapy-AIT) 
 Recipient BALB/c mice were inoculated subcutaneously into their shaven left 
flanks with 1 x 106 4T1 mammary tumor cells in 0.05ml phosphate buffered saline of 
pH7.4 (PBS). These tumor bearing mice were then randomly divided into five 
experimental groups: 1) untreated control, 2) CYP-only treated control, 3) CYP and GEM 
treated, 4) CYP and AIT and 5) CYP, GEM and AIT treated group. Nine days after 4T1 
flank injection, cyclophosphamide (CYP) groups received 100mg/kg of CYP 
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intraperitoneally (ip) on the left flank. The first administration of in vivo gemcitabine 
(GEM) was also given on this day at 60mg/kg intraperitoneally (ip) on the right flank. A 
subsequent GEM administration was given on weekly basis from this day on. Twenty-four 
hours later after first day administration (day 10), 75 million of IL7/15-expanded DLN 
cells for AIT were infused iv in 0.5ml of PBS, 10 days after flank inoculation. 
Tumor Measurements 
 Flank tumor growth was monitored by biweekly measurements of perpendicular 
diameters using calipers. When the tumor area (calculated as a product of the two 
perpendicular measurements) was greater than 100mm2 or if the mouse appeared sick, the 
animal was euthanized by CO2 inhalation.  
Sensitization of Spleen Cells and In Vitro Expansion of Splenocytes 
 BALB/c mice were inoculated subcutaneously into their shaven left flank with 
50,000 4T1 mammary cells. On the 20th day, mice were treated with 60mg/kg of GEM 
intraperitoneally. Six to 24 h after GEM treatment, spleens were harvested in complete 
RPMI, weighed, and crushed through a cell strainer. Splenocytes were resuspended in 1× 
ammonium chloride solution to lyse red blood cells and were stained with 0.04% trypan 
blue to exclude dead cells. The viable spleen cell numbers were counted under a light 
microscope using a Neubauer type hemacytometer. Splenocytes that were expanded were 
first subjected to Ficoll density gradient centrifugation to isolate splenic mononuclear cells. 
These cells were then washed and brought to a concentration of 1×106 cells/ml and 
activated by incubation with bryostatin, ionomycin and IL2 (as above) in 50 ml conical 
polystyrene tubes at 37 °C, 5% CO2, for 18 h. Cells were washed three times with warm 
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complete RPMI and resuspended at 1×106 cells/ml. Splenocytes were expanded in 
complete RPMI supplemented with an additional 5% heat-inactivated fetal calf serum with 
IL-7+IL-15 (10 ng/ml each, Peprotech Inc, Rocky Hill, NJ). The cells were allowed to 
proliferate in culture until peak growth was reached and were split every 2–3 days to 1×106 
cells/ml. 
Staining for Myeloid Derived Suppressor Cells (MDSC) 
 Spleen cells were washed with flow buffer (2% fetal bovine serum and phosphate 
buffered saline of pH7.4) and brought up to 1 x 106 cells/ml in 100μl. Cells were first 
treated with anti-mouse CD16/CD32 (Mouse BD Fc Block) (BD Pharmingen, San Diego, 
CA). Then the cells were stained for 30 minutes with: anti-mouse (FITC-conjugated) 
CD11b and anti-mouse (PE-conjugated) Ly-6G/Ly-6C(Gr-1) (Biolegend, San Diego, CA). 
Unstained cells were used as a negative control. FITC-conjugated rat IgM was used as the 
isotype control or CD11b and PE-conjugated rat IgG2a,λ was used as the isotype control for 
Ly-6G/Ly-6C(Gr-1) (Biolegend, San Diego, CA). Staining with anti-CD11b alone or anti-
Gr-1 alone was used as single color positive controls. Stained cells were analyzed (50,000 
viable cells per sample) on an ELITE Beckman Coulter flow cytometer. 
Separation of MDSC from Splenocytes 
 BALB/c mice were injected in the flank with 50,000 4T1 carcinoma cells. Twenty-
one days later, splenocytes were harvested and prepared as described above. Some 
splenocytes were set aside as a control group while the remaining cells were sorted to 
positively select out the myeloid derived suppressor cells using an Easy Sep PE Selection 
Kit (StemCell Technologies, Vancouver, BC, Canada). Splenocytes were treated with FcR 
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blocking antibody (BD Biosciences Pharmingen, San Diego, CA) and PE-conjugated anti-
mouse Ly-6G/Ly- 6C (Gr-1) (Biolegend, San Diego, CA). The positive MDSC cells 
adhered to the magnetic beads while the MDSC-depleted splenic lymphocytes were 
collected separately. Both the MDSC positive and depleted cell groups were counted using 
a Neubauer type hemacytometer, and the percentages of MDSC originally present were 
calculated. Using the total number of cells for the control groups as the starting point, the 
number of cells in the MDSC positive group and MDSC-depleted groups were adjusted by 
the calculated MDSC percentage to ensure that the same number of lymphocytes was 
plated in each well. In some groups, MDSCs removed with the magnetic beads were added 
back to the MDSC-depleted cells at a two-to-one splenic lymphocytesto- MDSC ratio. 
Then all groups of splenocytes (control group, MDSCdepleted group and MDSC-added-
back group)were activated with B/I plus IL-2 (80 U/ml), and expanded with a combination 
of IL-7 and IL-15 (10 ng/ml). 
Proliferation Assay 
 Splenic lymphocytes (unseparated, MDSC-depleted or with MDSC added back, as 
described above) were activated with B/I plus IL-2, and cultured in IL-7 and IL-15. On day 
4, the activated cells were added to 96-well plates at 5×104 cells/well. After 2 days of 
culture, the cells were labeled with 1 μCi/ml of [3H] thymidine (PerkinElmer Life and 
Analytical Sciences, Boston, MA) and were harvested 24 h later with a semi-automated 
harvester (PHD: Cambridge Technology, Inc., Cambridge, MA). Thymidine uptake was 
determined by liquid scintillation counting and expressed as the mean cpm±SD of triplicate 
wells. 
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Statistical Analysis 
 Differences between two groups were analyzed with the Student's t-test. 
Differences among more than two groups were examined by analysis of variance 
(ANOVA) and Tukey–Kramer honestly significant difference test (Tukey's HSD) using 
JMPIN software (SAS Institute Inc., Cary, N.C.). Results of tumor growth are presented as 
the means±standard errors (SE) of tumor area in each treatment group. In vivo experiments 
included three to six mice per group. In vitro assays were repeated at least twice. A p < 
0.05 was used throughout to determine significant differences. 
 
3.3 Results 
In vitro proliferation of splenic T lymphocytes from 4T1 tumor-bearing mice is suppressed 
by MDSCs 
 BALB/c mice were inoculated subcutaneously in the flank with 50,000 4T1 
mammary carcinoma cells. Twenty-one days later, spleens were harvested and MDSCs 
were depleted using the magnetic beads. All experimental groups, the unseparated tumor 
bearing splenocytes (TB control), MDSC-depleted splenocytes (TB MDSC depleted), and 
splenic lymphocytes with MDSC added back in a similar proportion to what was removed 
(TB MDSC first depleted then MDSC added back) were pulsed for 18h with bryostatin-1 
(5nM), ionomycin (1mM), and IL-2 (80U/ml) then expanded for 8 days in IL-7/15 
(10ng/ml). Figure 5A shows the expansion curves for all three groups. The MDSC-
depleted group viable cell number expanded 23.4 fold, and both the control groups with 
MDSCs showed suppression of growth. Figure 5B shows similar results of proliferation of 
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lymphocytes measured by thymidine incorporation. Each cell group was pulsed with 3H-
thymidine on day 5 and cells were harvested for beta-scintillation counting the following 
day.   
In vivo administration of Gemcitabine reduces MDSCs in the tumor bearing host spleen 
 Using two-color flow cytometry, the number of CD11b+ and Gr-1+ (MDSCs) 
population was analyzed in mice bearing large 4T1 flank tumors. As shown in Figure 6, 
CD11b+ Gr-1+ cells made up 29.5% of the spleen cells in an animal bearing a large tumor 
(100 mm2 in size). Gemcitabine was able to reduce this CD11b+ Gr-1+ cell population 
with a single dose of 60mg/kg administered shortly before spleen harvest. Even after a 
short period of 6h of GEM treatment, the percentage of CD11b+ Gr-1+ cells in the tumor 
spleens begins to decrease to 22.7%. By 12h and 24h, the MDSC population was reduced 
to 18.3% and 17.7 % respectively.  
Gemcitabine-treated 4T1 tumor bearing host failed to reduce the late stage 4T1 flank tumor 
 Recipient BALB/c mice were inoculated subcutaneously with 50,000 4T1 
mammary tumor cells in the flank. After 9 days, cyclophosphamide (CYP) groups received 
100mg/kg of CYP intraperitoneally (ip) on the left flank. The first administration of in vivo 
gemcitabine (GEM) was also given on this day at a concentration of 60mg/kg. A 
subsequent GEM administration was given on a weekly basis from this day on. On day 10, 
IL7/15-expanded DLN cells were infused iv. As shown in Figure 7B, despite our previous 
findings of GEM’s cytotoxicity in vitro to 4T1 cells and its inhibiting effects on MDSCs in 
vivo, rapid 4T1 tumor kinetics inhibited a complete tumor regression and therapeutic 
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effects of this combination chemo-immunotherapy. AIT alone carried out under the same 
conditions did not inhibit tumor growth. 
 
3.4 Discussion 
 Tumor-induced immunosuppression is a major obstacle to successful 
immunotherapy and a possible mechanism of tumor escape from immunosurveillance (52, 
56). Several studies have identified myeloid-derived suppressor cells (MDSC) with 
phenotype of CD11b+ Gr-1+ as an important contributor to tumor immune evasion (50, 54, 
56, 57). A significant increase in the level of MDSC in tumor-bearing spleens and bone 
marrow is associated with impaired immune reactivity (48). Accumulation of MDSC in 
both preclinical models and in human samples has been shown to be associated with 
defective dendritic cell function and inhibition of antigen specific T cell responses (57). 
Our findings here show that the presence of MDSC suppresses in vitro proliferation of 
splenic T cells harvested from tumor-bearing hosts. On the other hand, depletion of MDSC 
restored in vitro proliferative capacity. 
 The mechanisms of MDSC-mediates immunosuppression are diverse. One pathway 
involves nitric oxide (NO) as an intercellular multivalent signaling molecule. NO is 
synthesized by the oxidation of L-arginine to L-citrulline and NO, a reaction catalyzed by a 
family of enzymes called nitric oxide synthases (NOS) and other cofactors including 
flavones, tetrahydrobiopterin, and Ca2+. Three types of NOS are known: types 1 and 3 are 
constitutively expressed in neuronal tissue and endothelium. An inducible form of NOS 
(iNOS or type 2) is expressed in a variety of tissue and cell types, including vascular 
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endothelium and macrophages. NO released by MDSC works downstream of the IL-2 
receptor, inhibiting the phosphorylation of STAT5, Erk, and Akt, three components of the 
IL-2 receptor signaling pathway. NO can also interfere with signaling of many other 
cytokines such as IL-1, IL-6, IL-8, IL-10, IL-12, IFN-γ, TNF-α, and TGF-β. Animal 
studies with NOS inhibitors and depletion of iNOS have shown NO to be as an important 
mediator of MDSC-mediated immunosuppression. In vitro and in vivo studies performed 
in iNOS-/- knockout mice indicated that NO was required to inhibit T cell proliferation in 
the presence of MDSC. Also, in the presence of superoxide, NO gives rise to peroxynitrite 
(ONOO-). Peroxynitrite induces antigen-primed T lymphocyte apoptosis by inhibiting 
protein tyrosine phosphorylation via nitration of critical tyrosine residues. However, the 
inhibition of T cell proliferation in the presence of either splenic or bone marrow MDSC 
from tumor bearing mice was completely reversed when an iNOS inhibitor and a 
superoxide dismutase mimetic were added. Suppressive mechanisms that allow MDSC to 
inhibit CD8 function require cell-cell contact. This contact is not to induce T lymphocyte 
apoptosis but rather to trigger NO secretion by MDSC by IFN-γ (58). Furthermore, tumor-
infiltrating MDSC seem to be the primary source of ARG1 activity in tumors, and 
treatment with ARG1 inhibitors impairs tumor formation in immunologically intact mice. 
Increased ARG1 activity by MDSC has been linked to reduced CD3ζ chains in T cells and 
diminished production of IL-2 and IFN-γ. ARG1 activity also leads to depletion of L-
arginine in the local tumor environment, which induces iNOS to produce superoxide (46). 
 Other suppressive mechanisms that allow MDSC to inhibit T cell immunity involve 
IL-12 and IL-10 production. MDSC can downregulate IL-12 production by macrophages 
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and increase their own production of IL-10 in response to signals from macrophages. IL-12 
produced by macrophages promotes tumoricidal natural killer cell activity. MDSC may 
minimize this NK activity by downregulating IL-12 production. MDSC release of IL-10 
interferes with DC maturation and high levels of IL-10 may indirectly block DC function 
(47). 
 Thus, eliminating these myeloid immunosuppressive cells in vivo has been a goal 
with the potential of enhancing the antitumor activities of transferred T cells in adoptive 
immunotherapy. Surgical removal of the cancer has shown a short-term reduction of 
MDSC and restoration of antitumor immunity, though, surgical removal of most metastatic 
tumors is not possible. Depletion of MDSC by treating tumor-bearing mice with Gr-1 
antibodies has also been linked to reduction of MDSC and reduced tumor growth. 
However, because of poor specificity of the Gr-1 monoclonal antibodies, mature 
granulocytes were also eliminated, jeopardizing the host’s immune system (58). 
Kusmartsev et al. demonstrated both in vitro and in vivo that administration of all-trans-
retinoic acid can dramatically reduce the number of MDSC in tumor-bearing animals and 
increased antitumor CD4 and CD8 T cell responses.  
 More recently, the cytotoxic chemotherapy agent, gemcitabine, has been combined 
with AIT to reduce MDSC and enhance antitumor activity. GEM is a commonly used 
agent in combination chemotherapy for the treatment of several types of cancers 
(mammary, bladder, lung, and pancreatic cancers). Gemcitabine HCl (GEM), 2’-deoxy-2’, 
2’-difluorocytidine monohydrochloride (β-isomer), is a nucleoside analogue of cytidine 
that halts the DNA synthesis phase (S-phase) and blocks the progression of cells through 
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the G1/S-phase boundary, which targets rapidly diving tumor cells (53). GEM has been 
reported not only to reduce MDSC but also to lower IL-10 levels, thus, restoring 
macrophage production of IL-12 (47). Also, GEM can induce apoptosis of tumor cells, 
which can generate more antigen cross presentation. In this report, we showed that even a 
short 6 hour GEM in vivo treatment reduces MDSC in the spleens of tumor-bearing mice. 
By 24 hour, MDSC were significantly reduced. Accordingly, Suzuki et al. administered a 
single dose of GEM (120 mg/kg) in vivo, similar to the equivalent dose used in patients 
and observed reduction in MDSC accompanied by increased antitumor activity of CD8 T 
cells and activated natural killer cells. Ko et al. also used GEM (60 mg/kg) combined with 
immunotherapy to treat Her2/neu induced mammary tumors and showed that this 
combined chemotherapy and immunotherapy induced therapeutic antitumor immunity (54, 
59). 
In our previous report, we found that GEM can reduce the number of CD11b+ Gr-
1+ population by both its direct inhibitory effect on MDSC and indirectly as a result of its 
cytotoxicity to the tumor cells (55). By eliminating the tumors directly, the number of 
MDSC maintained by factors secreted from the tumor mass declined. Although GEM 
reduced MDSC and restored T cell in vitro functions of splenocytes prepared for AIT, 
these splenic T cells still failed to induce tumor regression when transferred to treat 4-day 
established 4T1 flank tumors. In this report, we aimed to treat a large 10 day established 
4T1 flank tumor (>60mm2) by treating the AIT recipients with gemcitabine. Moreover, we 
have prepared the T lymphocytes for AIT from tumor DLN cells which were stimulated in 
vitro with B/I and cultured in IL-7/15 for 10 days before AIT. Unlike our previous AIT 
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attempts with a limited number of splenic T cells, we have transferred a maximum cell 
dose (75 million cells) of T lymphocytes to treat large 4T1 tumors. Despite the successful 
AIT preparation, combined therapy of GEM and AIT failed to induce significant tumor 
regression of such large established tumors. Also, unlike Suzuki et al. who administered 
120 mg/kg of GEM, we used a lower GEM dose (60 mg/kg) to lessen the adverse effects 
of the antineoplastics on the activated tumor-specific cytotoxic T cells. Thus, although 
GEM treatment can attenuate the MDSC-mediated tumor-suppressive environment, when 
treating large tumors in the future, it should be accompanied by other methods such as 
surgery or additional cytotoxic agents. 
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Figure 5. In vitro proliferation of splenic T lymphocytes from 4T1 tumor-bearing 
mice is suppressed by MDSCs. 
 
BALB/c mice were inoculated subcutaneously in the flank with 50,000 4T1 mammary 
carcinoma cells. Twenty-one days later, spleens were harvested and MDSCs were depleted 
using the magnetic beads. All experimental groups, the unseparated tumor bearing 
splenocytes (TB control), MDSC-depleted splenocytes (TB MDSC depleted), and splenic 
lymphocytes with MDSC added back in a similar portion to what was removed (TB 
MDSC first depleted then MDSC added back) were pulsed for 18h with bryostatin-1 
(5nM), ionomycin (1mM), and IL-2 (80U/ml) then expanded for 8 days in IL-7/15 
(10ng/ml). Figure 5 (A) shows the expansion curves for all three groups. The MDSC-
depleted group expanded to 23.4 fold increase in cell number while both the control groups 
with MDSCs showed suppression in growth. Figure 5 (B) shows similar results of 
proliferation of lymphocytes measured by thymidine incorporation. Each cell groups were 
pulsed with 3H-thymidine on day 5 and cells were harvested for beta-scintillation counting 
the following day. Data shown are representative of three independent experiments. 
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Figure 5A 
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Figure 5B 
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Figure 6: In vivo administration of Gemcitabine reduces MDSCs in the tumor 
bearing host spleens 
 
Using two-color flow cytometry, the number of CD11b+ and Gr-1+ (MDSCs) population 
was analyzed in mice bearing large 4T1 flank tumors. As shown in Figure 6, CD11b+ Gr-
1+ cells made up 29.5% of the spleen cells in an animal bearing a large tumor (100 mm2 in 
size). Gemcitabine was able to reduce this CD11b+ Gr-1+ cell population with a single 
dose of 60mg/kg in vivo administration. Even after a short period of 6h of GEM treatment, 
the percentage of CD11b+ Gr-1+ cells in the tumor spleens begins to decrease to 22.7%. 
By 12h and 24h, the MDSC population has been reduced to 18.3% and 17.7 % 
respectively. Data shown are representative of three independent experiments. 
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Gr1 
Tumor Only 6h GEM treatment
24h GEM treatment12h GEM treatment
CD11b  
 
 
 
 
 
 
 
 
 
 
 61
   
Figure 7: Adoptive immunotherapy of 75 million IL-7/15 cultured DLN cells in 
combination with in vivo administration of GEM were ineffective against 10 day old 
subcutaneous 4T1 flank tumors.  
 Recipient BALB/c mice were inoculated subcutaneously into their shaven left flank 
with 1 x 106 4T1 mammary tumor cells in 0.05ml phosphate buffered saline of pH7.4 
(PBS). These tumor bearing mice were then randomly divided into five experimental 
groups: 1) untreated control, 2) Cyclophosphamide-only treated control (CYP only), 3) 
Cyclophosphamide and gemcitabine treated (CYP & GEM), 4) Cyclophopshamide and 
AIT (CYP & AIT) and 5) CYP, GEM and AIT treated group (CYP/GEM & AIT). After 9 
days of 4T1 flank injection, cyclophosphamide (CYP) groups received 100mg/kg of CYP 
intraperitoneally (ip) on the left flank. The first administration of in vivo gemcitabine 
(GEM) was also given on this day concentration of 60mg/kg on the right flank. A 
subsequent GEM administration was given on weekly basis from this day on. Twenty-four 
hours later, 75 million (max dose) of IL7/15-expanded DLN cells for AIT were infused iv 
in 0.5ml of PBS, 10 days after flank inoculation. (A) IL-7/15 cultured DLNs expanded to 
65 fold by day 10 (AIT day) (B) Data shown is mean tumor area ± SE (6 mice per group). 
A significant difference in mean tumor area was found using ANOVA and Tukey-Kramer 
honestly significant difference test (Tukey’s HSD) using JMPin software. 
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Figure 7A 
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The Host Defense Mechanisms. 
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APPENDIX B 
 
 Recipient BALB/c mice were inoculated subcutaneously 50,000 4T1 mammary 
carcinoma. These tumor bearing mice were then randomly divided into five experimental 
groups:  
 1) Untreated control 
 2) Cyclophosphamide-only treated control (CYP) 
 3) Cyclophosphamide and AIT with IL-2 expanded 20 million DLN cells (CYP + 
 AIT (IL-2 20)) 
 4) AIT with IL-2 expanded 40 million DLN cells (CYP + AIT (IL-2 40))  
 5) AIT with IL-7/15 expanded 20 million DLN cells (CYP + AIT (IL-7/15 20))  
 6) AIT with IL-7/15 expanded 40 million DLN cells (CYP + AIT (IL-7/15 40)) 
 7) AIT with IL-7/15 expanded 80 million DLN cells (CYP + AIT (IL-7/15 80)) 
After 3 days of 4T1 flank injection, cyclophosphamide (CYP) groups received 100mg/kg 
of CYP intraperitoneally (ip) on the left flank. AIT was performed the following day to 
cure 4 day tumor. All IL-7/15 AIT group induced complete tumor regression while IL-2 
AIT group had similar kinetics as the CYP only control group. Data shown is mean tumor 
area ± SE (6 mice per group). A significant difference in mean tumor area was found using 
ANOVA and Tukey-Kramer honestly significant difference test (Tukey’s HSD) using 
JMPin software 
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